Evidence map›Paper›PMID 28569148›Full record

ArticleBMC infectious diseases2017

Diagnostic accuracy and usefulness of the Genotype MTBDRplus assay in diagnosing multidrug-resistant tuberculosis in Cameroon? a cross-sectional study.

Ngu Njei Abanda, Josiane Yvonne Djieugoué, Eunjung Lim, Eric Walter Pefura-Yone, Wilfred Fon Mbacham, Guy Vernet, Veronique Mbeng Penlap, Sara Irene Eyangoh, Diane Wallace Taylor, Rose Gana Fomban Leke

Abstract read
In one paragraph

Article in BMC infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Absence of hybridization with the wild-type and mutant rpoB probes in the Genotype MTBDRplus assay detects 'disputed' rifampicin mutations.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2018
    Article
  12. Multi-drug resistantAfrican journal of laboratory medicine · 2018
    Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ngu Njei AbandaBiotechnology Centre, University of Yaounde I, PO Box: 3851, Yaounde, Cameroon. abandann@hawaii.edu.
Josiane Yvonne DjieugouéMycobacteriology Service, Centre Pasteur of Cameroon, PO Box: 1274, Yaounde, Cameroon.
Eunjung LimOffice of Biostatistics and Quantitative Health Sciences, University of Hawaii, Honolulu, HI, 96813, USA.
Eric Walter Pefura-YonePneumology service, Yaounde Jamot Hospital, P.O Box: 4021, Yaounde, Cameroon.
Wilfred Fon MbachamThe Biotechnology Centre, University of Yaoundé 1, BP, 8094, Yaoundé, Cameroon.
Guy VernetVirology Service, Centre Pasteur of Cameroon, P.O. Box 1274, Yaoundé, Cameroon.
Veronique Mbeng PenlapLaboratory for Tuberculosis Research (LTR), Biotechnology Centre (BTC)-Nkolbison, University of Yaoundé I, Yaoundé, Cameroon.
Sara Irene EyangohMycobacteriology Service, Centre Pasteur of Cameroon, PO Box: 1274, Yaounde, Cameroon.
Diane Wallace TaylorDepartment of Tropical Medicine, Medical Microbiology and Pharmacology, University of Hawaii, Honolulu, HI, 96813, USA.
Rose Gana Fomban LekeLaboratory of Immunology and Parasitology, the Biotechnology Centre, University of Yaoundé 1, Yaoundé, Cameroon.

Funding

The Role of gp120 on Cardiovascular Disease in People Living with HIVU54MD007601 · NIMHD · UNIVERSITY OF HAWAII AT MANOA · PI Jerris Robert Hedges · 2017 to 2026
$59.5M
RESEARCH DESIGN AND BIOSTATISTICS COREU54MD007584 · NIMHD · UNIVERSITY OF HAWAII AT MANOA · PI HEDGES, JERRIS ROBERT, MOKUAU, NOREEN · 2012 to 2018
$21.1M
RESEARCH DESIGN, BIOSTATISTICS AND RESEARCH ETHICS COREG12MD007601 · NIMHD · UNIVERSITY OF HAWAII AT MANOA · PI BERRY, MARLA J · 2012 to 2016
$13.0M
Training of Cameroonian Scientists in Research on MalariaD43TW009074 · FIC · UNIVERSITY OF HAWAII AT MANOA · PI NERURKAR, VIVEK RAMCHANDRA · 2011 to 2015
$978k
FIC NIH HHS D43 TW009074NIMHD NIH HHS G12 MD007601NIMHD NIH HHS U54 MD007584NIMHD NIH HHS U54 MD007601
6 · The paper itself

Abstract

backgroundDrug-resistant tuberculosis, especially multidrug-resistant tuberculosis (MDR-TB), is a major public health problem. Effective management of MDR-TB relies on accurate and rapid diagnosis. In this study, we assessed the diagnostic accuracy of the Genotype MTBDRplus assay in diagnosing MDR-TB in Cameroon, and then discuss on its utility within the diagnostic algorithm for MDR-TB.

methodsIn this cross-sectional study, 225 isolates of Mycobacterium tuberculosis cultured from sputum samples collected from new and previously treated pulmonary tuberculosis patients in Cameroon were used to determine the accuracy of the Genotype MTBDRplus assay. We compared the results of the Genotype MTBDRplus assay with those from the automated liquid culture BACTEC MGIT 960 SIRE system for sensitivity, specificity, and degree of agreement. The pattern of mutations associated with resistance to RIF and INH were also analyzed.

resultsThe Genotype MTBDRplus assay correctly identified Rifampicin (RIF) resistance in 48/49 isolates (sensitivity, 98% [CI, 89%-100%]), Isoniazid (INH) resistance in 55/60 isolates (sensitivity 92% [CI, 82%-96%]), and MDR-TB in 46/49 (sensitivity, 94% [CI, 83%-98%]). The specificity for the detection of RIF-resistant and MDR-TB cases was 100% (CI, 98%-100%), while that of INH resistance was 99% (CI, 97%-100%). The agreement between the two tests for the detection of MDR-TB was very good (Kappa = 0.96 [CI, 0.92-1.00]). Among the 3 missed MDR-TB cases, the Genotype MTBDRplus assay classified two samples as RIF-monoresistant and one as INH monoresistant. The most frequent mutations detected by the Genotype MTBDRplus assay was the rpoB S531 L MUT3 41/49 (84%) in RIF-resistant isolates, and the KatG S315 T1 (MUT1) 35/55 (64%) and inhA C15T (MUT1) 20/55 (36%) mutations in INH-resistant isolates.

conclusionThe Genotype MTBDRplus assay had good accuracy and could be used for the diagnosis of MDR-TB in Cameroon. For routine MDR-TB diagnosis, this assay could be used for Mycobacterium tuberculosis cultures containing contaminants, to complement culture-based drug susceptibility testing or to determine drug resistant mutations.

Indexed as

AdultAntitubercular AgentsBacterial ProteinsCameroonCross-Sectional StudiesFemaleGenotypeGenotyping TechniquesHumansIsoniazidMaleMicrobial Sensitivity TestsMiddle AgedMolecular Diagnostic TechniquesMutationMutation RateAntitubercular AgentsBacterial ProteinsInhA protein, MycobacteriumIsoniazidOxidoreductasesRifampinCameroon. InhA promoter mutationGenotype MTBDRplus assayKatG codon 315 mutationMultidrug-resistant tuberculosis (MDR-TB)Pulmonary tuberculosisrpoB mutations

Identifiers

PMID28569148
PMCPMC5452623

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.